title: Extended recombinant bacterial ghost system.
abstract: Controlled expression of cloned PhiX174 gene E in Gram-negative bacteria results in lysis of the bacteria by formation of an E-specific transmembrane tunnel structure built through the cell envelope complex. Bacterial ghosts from a variety of bacteria are used as non-living candidate vaccines. In the recombinant ghost system, foreign proteins are attached on the inside of the inner membrane as fusions with specific anchor sequences. Ghosts have a sealed periplasmic space and the export of proteins into this space vastly extends the capacity of ghosts or recombinant ghosts to function as carriers of foreign antigens. In addition, S-layer proteins forming shell-like self assembly structures can be expressed in candidate vaccine strains prior to E-mediated lysis. Such recombinant S-layer proteins carrying foreign epitopes further extend the possibilities of ghosts as carriers of foreign epitopes. As ghosts have inherent adjuvant properties, they can be used as adjuvants in combination with subunit vaccines. Subunits or other ligands can also be coupled to matrixes like dextran which are used to fill the internal lumen of ghosts. Oral, aerogenic or parenteral immunization of experimental animals with recombinant ghosts induced specific humoral and cellular immune responses against bacterial and target components including protective mucosal immunity. The most relevant advantage of recombinant bacterial ghosts as immunogens is that no inactivation procedures that denature relevant immunogenic determinants are employed in this production. This fact explains the superior quality of ghosts when compared to other inactivated vaccines. The endotoxic component of the outer membrane does not limit the use of ghosts as vaccine candidates but triggers the release of several potent immunoregulatory cytokines. As carriers, there is no limitation in the size of foreign antigens that can be inserted in the membrane and the capacity of all spaces including the membranes, peri-plasma and internal lumen of the ghosts can be fully utilized. This extended recombinant ghost system represents a new strategy for adjuvant free combination vaccines.
authors.affiliation: Institute of Microbiology and Genetics, University of Vienna, Wien, Austria. oldfox@gem.univie.ac.at
authors.forename: W
authors.initials: W
authors.lastname: Lubitz
authors.forename: A
authors.initials: A
authors.lastname: Witte
authors.forename: F O
authors.initials: FO
authors.lastname: Eko
authors.forename: M
authors.initials: M
authors.lastname: Kamal
authors.forename: W
authors.initials: W
authors.lastname: Jechlinger
authors.forename: E
authors.initials: E
authors.lastname: Brand
authors.forename: J
authors.initials: J
authors.lastname: Marchart
authors.forename: W
authors.initials: W
authors.lastname: Haidinger
authors.forename: V
authors.initials: V
authors.lastname: Huter
authors.forename: D
authors.initials: D
authors.lastname: Felnerova
authors.forename: N
authors.initials: N
authors.lastname: Stralis-Alves
authors.forename: S
authors.initials: S
authors.lastname: Lechleitner
authors.forename: H
authors.initials: H
authors.lastname: Melzer
authors.forename: M P
authors.initials: MP
authors.lastname: Szostak
authors.forename: S
authors.initials: S
authors.lastname: Resch
authors.forename: H
authors.initials: H
authors.lastname: Mader
authors.forename: B
authors.initials: B
authors.lastname: Kuen
authors.forename: B
authors.initials: B
authors.lastname: Mayr
authors.forename: P
authors.initials: P
authors.lastname: Mayrhofer
authors.forename: R
authors.initials: R
authors.lastname: Geretschläger
authors.forename: A
authors.initials: A
authors.lastname: Haslberger
authors.forename: A
authors.initials: A
authors.lastname: Hensel
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000941:Antigens / Q000008:administration & dosage; D010584:Bacteriophage phi X 174 / Q000235:genetics; D001709:Biotechnology; D002462:Cell Membrane / Q000235:genetics; D002678:Chimera / Q000235:genetics; D004337:Drug Carriers; D015870:Gene Expression; D005814:Genes, Viral; D006090:Gram-Negative Bacteria / Q000235:genetics / Q000276:immunology; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D011995:Recombination, Genetic; D017778:Vaccines, Combined / Q000008:administration & dosage; D014614:Vaccines, Synthetic / Q000008:administration & dosage*
chemical_list: D000276:Adjuvants, Immunologic; D000941:Antigens; D004337:Drug Carriers; D018836:Inflammation Mediators; D017778:Vaccines, Combined; D014614:Vaccines, Synthetic